Načítá se...
Immunotherapy of advanced renal cell carcinoma: Current and future therapies
Previously a malignancy with few therapeutic options, metastatic renal cell carcinoma (mRCC) treatment is rapidly evolving. Although cytokine therapies (interferon-a, interleukin-2) have been used less frequently over the past decade, recent approval of an immune checkpoint inhibitor, nivolumab, has...
Uloženo v:
| Vydáno v: | Hum Vaccin Immunother |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215367/ https://ncbi.nlm.nih.gov/pubmed/27494417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1212794 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|